Deferred Tax Assets, Valuation Allowance of Oruka Therapeutics, Inc. from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Oruka Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
  • Oruka Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $48,716,000, a 129% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Oruka Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $48,716,000 +$27,399,000 +129% 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q4 2024 $21,317,000 -$34,214,000 -62% 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q4 2023 $55,531,000 +$1,159,000 +2.1% 31 Dec 2023 10-K 01 Feb 2024 2023 FY
Q4 2022 $54,372,000 +$2,254,000 +4.3% 31 Dec 2022 10-K 01 Feb 2024 2023 FY
Q4 2021 $52,118,000 +$5,128,000 +11% 31 Dec 2021 10-K 24 Feb 2023 2022 FY
Q4 2020 $46,990,000 +$2,363,000 +5.3% 31 Dec 2020 10-K 14 Mar 2022 2021 FY
Q4 2019 $44,627,000 +$1,098,000 +2.5% 31 Dec 2019 10-K 18 Mar 2021 2020 FY
Q4 2018 $43,529,000 +$1,901,000 +4.6% 31 Dec 2018 10-K 18 Feb 2020 2019 FY
Q4 2017 $41,628,000 -$13,151,000 -24% 31 Dec 2017 10-K 27 Feb 2019 2018 FY
Q4 2016 $54,779,000 +$6,159,000 +13% 31 Dec 2016 10-K 22 Mar 2018 2017 FY
Q4 2015 $48,620,000 +$4,120,000 +9.3% 31 Dec 2015 10-K 21 Mar 2017 2016 FY
Q4 2014 $44,500,000 31 Dec 2014 10-K 19 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.